Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.

 

Important Public Notice: ANCC Magnet Recognition Program® - Site Visit through November 4, 2022. Click here to learn more.

MENU

Fox Chase Researchers Show Efficacy of Gene Therapy in Treating Cystathionine β-synthase Deficiency in Mouse Models

February 1, 2022

Dr. Warren D. Kruger, author on the study and professor in the Molecular Therapeutics research programDr. Warren D. Kruger, author on the study and professor in the Molecular Therapeutics research program

PHILADELPHIA (February 1, 2022)—In a recent study, researchers at Fox Chase Cancer Center found that gene therapy using a genetically engineered viral vector was highly effective in treating cystathionine β-synthase deficiency (CBS) in mice.

CBS deficiency is a rare inherited genetic disorder that inactivates the enzyme that breaks down the toxic sulfur-containing amino acid homocysteine. The disease is characterized by elevated levels of homocysteine in the blood, resulting in symptoms including stroke, dislocated lenses, osteoporosis, and behavioral/cognition issues.   

Patients diagnosed with CBS deficiency are currently treated by a combination of vitamin supplementation and restriction of foods containing the homocysteine precursor methionine, but the effectiveness of this therapy is limited due to poor compliance with the very strict dietary regime.

“Our lab has been experimenting with a genetically engineered adeno-associated virus, which is also known as rAAV, that delivers the human CBS gene to the liver. The AAV-based gene therapy field is quite exciting right now, as the first few approvals have now been given to several products by the Food and Drug Administration for other rare genetic diseases,” said Warren D. Kruger, PhD, an author on the study and professor in the Molecular Therapeutics research program at Fox Chase.

Kruger’s lab collaborated with Ronald G. Crystal, MD, chair of the Department of Genetic Medicine at Weill Cornell Medicine, to create a recombinant virus that expresses human CBS at high levels in the liver. “Dr. Crystal’s lab produced the virus and we tested the virus in our mouse model of CBS deficiency,” Kruger said. Crystal is an inventor on a pending patent application related to the processes and products based on this work.

In the study, mice were given a single dose of the virus and observed for up to a year. Treated mice had either full or substantial correction of alopecia, bone loss, and fat mass phenotypes associated with CBS deficiency in mice.

“We recognize that the importance of gene therapy is looking at durability. In our hands, mice can live a maximum of about three years and CBS-deficient mice have lives that are a little shorter. We felt that following these mice for a year—a third or their lifespan—would be a good amount to see how they were progressing. After that year, we essentially couldn’t distinguish the treated mice from the control heterozygous mice,” said Kruger.

He added that although the results of the study were reassuring, there are remaining questions related to long-term efficacy of the treatment. “We did see some changes over the course of the year. After a month, we saw a 97% reduction of homocysteine. After a year it was at 81%. The question would be, in humans, what does a year represent? Would it represent 30 years because mice only live three years, or would we see that sort of change after one year,” said Kruger. “If that’s the case, we would have to figure out a way to re-dose every few years.”

Despite those questions, Kruger said findings from the study still show that this AAV-based gene therapy is highly effective in treating CBS deficiency in mice. The results suggest that additional preclinical testing should be pursued to explore potential use in human trials.

The study, “Long-Term Functional Correction of Cystathionine β-Synthase Deficiency in Mice by Adeno-Associated Viral Gene Therapy,” was published in the Journal of Inherited Metabolic Disease.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Connect with Fox Chase